Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments

Jianchun Duan†, Yueqin Hao†, Rui Wan†, Sifan Yu†, Hua Bai†, Tongtong An†, Jun Zhao†, Zhijie Wang†, Minglei Zhuo† & Jie Wang†

1 Department of Thoracic Medical Oncology, Beijing Cancer Hospital, Beijing Institute of Cancer Research, Beijing, China
2 Department of Respiratory Medicine, Qingdao Municipal Hospital, Qingdao, China

Keywords
Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel); non-small-cell lung cancer (NSCLC); secreted protein acidic and rich in cysteine (SPARC).

Abstract

Background: The study was conducted to evaluate the efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) treatment in patients with advanced non-small-cell lung cancer (NSCLC) who have undergone multi-line therapy, and to investigate the association of secreted protein acidic and rich in cysteine (SPARC) expression status with clinical outcome.

Methods: Sixty-four patients who received NAB-paclitaxel treatment (130 mg/m² on days 1 and 8 of a 21 day cycle) as third line or further systemic treatment from 1 May 2011 to 30 June 2014 were included in this retrospective analysis. Tumor tissue was available in 28 patients for analysis of SPARC expression by immunohistochemistry.

Results: Sixty-two patients had response evaluation and complete survival follow-up data; 83.9% received the weekly NAB-paclitaxel as fourth-line treatment or beyond. The objective response and disease control rates (n = 62) were 16.1% (10/62) and 64.5% (40/62), respectively. The median progression-free and overall survival rates were 3.7 (95% confidence interval 2.6–4.8) and 9.8 months (95% confidence interval 6.9–12.8), respectively. Previous treatment with taxane did not affect the response to NAB-paclitaxel. The main grade 3–4 toxicities experienced were neutropenia (9.4%) and leukopenia (7.8%). Patients with SPARC expression in tumor stroma but not in cancer cells had poorer progression-free survival compared with those with negative SPARC expression in tumor stroma cells (3.3 vs. 5.0 months, P = 0.036).

Conclusion: Weekly NAB-paclitaxel might be effective for heavily pretreated NSCLC patients. SPARC expression in tumor stroma cells might be a potential negative predictor of NAB-paclitaxel.

Introduction

Lung cancer is the most common malignant disease and the leading cause of cancer-related death worldwide.1 With the development of novel antitumor agents, including targeted and anti-emetic drugs of low toxicities, more and more patients at advanced stage can maintain good performance status in order to continue subsequent treatment after completing standard first and second-line treatments. However, there are few recommendations for third-line chemotherapy or beyond for these patients and palliative care remains the standard approach. Chemotherapy drugs that can present good, well-tolerated clinical outcomes in patients who have failed multi-line therapy are urgently required.

Paclitaxel is one of the most widely used and effective antitumor agents derived from natural sources and plays
an important role in non-small-cell lung cancer (NSCLC). Traditional solvent-based paclitaxel is associated with hypersensitivity reactions to the polyoxyethylated castor oil in which it is dissolving. Therefore, pretreatment with a large quantity of drugs, such as corticosteroids and antihistamines, is required. As is universally known, many patients with lung cancer have a series of comorbidities, such as hypertension and diabetes, which limit the use of high dose steroids. Nanoparticle albumin-bound paclitaxel (NAB-paclitaxel) is an albumin-bound formulation of paclitaxel and allows the administration of paclitaxel without the use of lipid-based solvents, which reduces the risk of hypersensitive reactions, and can therefore be administered without the need for corticosteroid and antihistamine premedication. 

Furthermore, albumin has the potential to increase drug delivery to tumors. Equitoxic doses of NAB-paclitaxel have been much higher than those of traditional paclitaxel in both preclinical and clinical studies. NAB-paclitaxel has been studied as a first-line therapy and has achieved convincing antitumor activity in advanced NSCLC patients. However, compared with the standard first-line regimen of paclitaxel in combination with platinum, NAB-paclitaxel alone did not present a better clinical outcome. As a first-line therapeutic strategy, NAB-paclitaxel failed to demonstrate any advantage beyond previous standard chemotherapy and is less cost-effective than traditional paclitaxel. However, there is currently limited evidence to indicate that NAB-paclitaxel may be a subsequent choice for advanced NSCLC patients who have failed multi-lines of chemotherapy and targeted therapy.

Notably, albumin has the natural ability to promote drug delivery to tumors by initiating albumin receptor (gp60)-mediated transcytosis across endothelial cells, accumulating the drug in tumors by binding to secreted protein acidic and rich in cysteine (SPARC), a well-known matricellular molecule involved in multiple processes in various cancers. SPARC may help to facilitate metastasis by increasing the migration and invasion capacity of prostate and breast cells in vitro. Several studies have shown that SPARC overexpression is associated with poor prognosis. Infante et al. investigated whether different distributions of SPARC expression in cancer or tumor stromal cells possessed different clinical significance for resectable pancreatic adenocarcinoma. The results showed that patients whose tumor stromal cells expressed SPARC had poor survival compared with those whose tumor stroma cells did not express SPARC (hazard ratio [HR] 1.89, 95% confidence interval [CI] 1.31–2.74; \( P = 0.001 \)). However, the relationship between the status of SPARC expression in tumor stromal cells and the efficacy of NAB-paclitaxel treatment in advanced NSCLC has been not investigated.

Herein, we retrospectively analyzed clinical outcome and safety in 64 advanced NSCLC patients who received weekly doses of NAB-paclitaxel as subsequent therapy after previous failed multi-line therapy. SPARC expression in cancer or tumor stroma cells and the relationship between SPARC expression and the response to NAB-paclitaxel was evaluated.

**Methods**

**Patients**

From 1 May 2011 to 30 June 2014 in our department, 64 consecutive patients received weekly NAB-paclitaxel as third-line (16.1%) or further (83.9%) chemotherapy treatment for recurrent advanced NSCLC. All patients had been histologically or cytologically diagnosed with NSCLC. Prior treatment with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or taxanes (paclitaxel or docetaxel) for advanced disease was permitted. All patients had an expected survival of ≥12 weeks with adequate hematologic, hepatic, and renal function. Eastern Cooperative Oncology Group performance status was 0–2. Patients with peripheral neuropathy were excluded. Detailed records of age, gender, smoking history, pathological diagnosis, tumor stage at NAB-paclitaxel administration, prior antitumor therapy, EGFR mutation status, and other clinical data were obtained from all patients. To investigate the relationship between response and SPARC expression in cancer or tumor stroma cells, we collected as many tumor tissue samples as possible. Only 28 patients had tumor tissue available for SPARC analysis. The Institutional Ethic Committee at Peking University Cancer Hospital approved this study.

**Methods**

Nanoparticle albumin-bound paclitaxel (Abraxane, Abraxis, Summit, NJ, USA; 100 mg/vial) was used as monotherapy at a dose of 130 mg/m² (intravenous infusion for 30 minutes). The drug was administered on days 1 and 8 in a cycle. Treatment was repeated every three weeks until disease progression or unacceptable toxicity. Two patients could not tolerate the continuous NAB-paclitaxel therapy because of serious adverse events, thus we only have an evaluation of their safety data. The remaining 62 patients received at least one cycle of NAB-paclitaxel and were included in the response analyses. Objective efficacy was evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 every two cycles, except when patients’ symptoms obviously deteriorated. Tumor responses were analyzed based on the investigator’s evaluation of radiologically and clinically detected target...
lesions, including complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD), objective response rate (ORR = CR + PR), and disease control rate (DCR = CR + PR + SD). Adverse events (AEs) were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 4.0. Progression-free survival (PFS) was defined as the time from the first administration of NAB-paclitaxel to the first objective progression of disease. Overall survival (OS) was defined as the time from the first administration of NAB-paclitaxel to death or loss of follow-up. If the patient remained alive at the last follow-up, the data was treated as censored. The authors had access to identifying information during and after data collection.

Immunohistochemistry

Immunohistochemistry (IHC) was used to demonstrate the presence and location of SPARC in tumor tissue samples. Briefly, dried five-micron slides with formalin-fixed and paraffin-embedded tissue were prepared. Antigens were retrieved using ethylene-diamine-tetraacetic acid buffer and incubation at 100°C for 15 minutes. Slides were then incubated overnight at 4°C with monoclonal mouse anti-osteonectin/SPARC antibody (Invitrogen, Carlsbad, CA, USA) at 7 μg/mL. A two-step polymer-horseradish peroxidase method (GTVision, Beijing, China) was used for detection and 3,3′-diaminobenzidine-tetrahydrochloride staining. No staining was observed for the negative control, which was incubated with phosphate buffered saline instead of monoclonal mouse anti-osteonectin/SPARC antibody. Positive IHC was defined if more than 10% of cancer or tumor stroma cells were stained. Two different pathologists independently evaluated the results of IHC staining.

Statistical methods

All data were summarized descriptively, and two-sided 95% CIs were presented. PFS and OS were summarized using Kaplan–Meier methods. The indexes affecting PFS and OS were analyzed using the Cox regression model.

Results

The baseline characteristics of the 62 patients are presented in Table 1 (except the two patients who discontinued chemotherapy as a result of severe adverse events). All patients were categorized as clinical stage IV; 83.9% of patients received NAB-paclitaxel as fourth-line therapy or beyond.

| Characteristic | Number of patients | Percentage (%) |
|---------------|--------------------|----------------|
| Age (years)   |                    |                |
| <65           | 50                 | 80.6           |
| ≥65           | 12                 | 19.4           |
| Gender        |                    |                |
| Female        | 27                 | 43.5           |
| Male          | 35                 | 56.5           |
| ECOG performance status |                |                |
| 0–1           | 51                 | 82.3           |
| 2             | 11                 | 17.7           |
| Tumor pathological type |          |                |
| Adenocarcinoma | 46                 | 74.2           |
| Squamous carcinoma | 14               | 22.6           |
| Non-small cell lung cancer | 2 | 3.2 |
| Line of chemotherapy |        |                |
| 3 lines       | 10                 | 16.1           |
| ≥4 lines      | 52                 | 83.9           |
| Smoking history |                  |                |
| Smoker        | 30                 | 48.4           |
| Non-smoker    | 32                 | 51.6           |
| EGFR gene     |                    |                |
| Wild-type     | 39                 | 62.9           |
| Mutant        | 21                 | 33.9           |
| Unknown       | 2                  | 3.2            |
| Pre-existing comorbidities |        |                |
| Yes           | 27                 | 43.5           |
| No            | 35                 | 56.5           |

ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.

Efficacy

Response evaluation was performed for 62 patients. The ORR for NAB-paclitaxel was 16.1% (10/62) and the DCR (CR + PR + SD) was 64.5% (40/62). Up to 30 November 2016, the median PFS was 3.7 months (95% CI 2.6–4.8) and the median OS was 9.8 months (95% CI 6.9–12.8) (Fig 1). All nine patients with PR were diagnosed with adenocarcinoma, eight had received previous solvent-based paclitaxel or docetaxel therapy, and eight received NAB-paclitaxel as fourth-line or further chemotherapy.

Epidermal growth factor receptor mutation status was detected in 60 patients and 21 (32.3%) cases presented EGFR mutation. No statistically significant differences in PFS and OS after NAB-paclitaxel treatment were observed between EGFR mutated and wild-type patients (P > 0.05). Two of the patient samples were insufficient; therefore the pathology could not be further classified. No correlations were observed between age, gender, pathology, PS status, or previous antitumor therapy and clinical outcome of NAB-paclitaxel (Table 2). Cox regression analysis showed that response was related with both OS and PFS (Fig 2). Pearson’s correlation analysis was conducted to further determine whether previous solvent-based paclitaxel or

Table 1 Baseline characteristics of patients treated with NAB-paclitaxel (n = 62)
docetaxel treatment could influence the response to NAB-paclitaxel. Our results indicated that previous treatment with solvent-based paclitaxel or docetaxel did not affect the response to NAB-paclitaxel. However, patients who achieved disease control after taxane treatment had a tendency to present better efficacy of subsequent NAB-paclitaxel treatment than patients in whom taxane treatment had failed, although the results did not reach statistical significance (DCR 72.4% vs. 47.6%, \( P = 0.075 \)) (Table 3).

![Graph](image1.png)

**Figure 1** (a) Progression-free survival (median PFS 3.7 months, 95% confidence interval 2.6–4.8 months) and (b) overall survival (median OS 9.8 months, 95% confidence interval: 6.8–12.8 months) curves of the 62 patients evaluated for response.

| Characteristic                                | N  | PFS (95% CI)          | \( P \) | OS (95% CI)          | \( P \) |
|-----------------------------------------------|----|-----------------------|--------|----------------------|--------|
| Age (years old)                               |    |                       |        |                      |        |
| <65                                           | 50 | 3.0 (2.0–4.0)         | 0.092  | 8.8 (5.9–11.7)       | 0.805  |
| ≥65                                           | 12 | 5.3 (3.8–6.8)         |        | 11.0 (0.1–21.9)      |        |
| Gender                                        |    |                       | 0.208  |                      | 0.057  |
| Male                                          | 35 | 2.9 (1.8–4.0)         |        | 7.4 (5.5–9.3)        |        |
| Female                                        | 27 | 4.4 (3.5–5.2)         |        | 13.8 (10.1–17.5)     |        |
| Pathology                                     |    |                       | 0.651  |                      | 0.610  |
| Adenocarcinoma                                | 46 | 3.3 (1.9–4.7)         |        | 10.7 (6.6–14.8)      |        |
| Squamous cell carcinoma                       | 14 | 3.7 (1.5–5.9)         |        | 8.0 (3.1–12.9)       |        |
| ECOG PS (before NAB-paclitaxel treatment)     |    |                       | 0.274  |                      | 0.536  |
| 0 – 1                                         | 51 | 3.1 (2.0–4.2)         |        | 8.8 (5.4–12.2)       |        |
| 2                                             | 11 | 5.0 (2.7–7.3)         |        | 11.9 (6.2–17.6)      |        |
| Response                                      |    |                       | 0.000  |                      | 0.000  |
| PR + SD                                       | 40 | 4.8 (4.2–5.4)         |        | 12.0 (8.7–15.3)      |        |
| PD                                            | 22 | 1.6 (1.1–2.1)         |        | 4.8 (2.7–6.9)        |        |
| Smoking status                                |    |                       | 0.515  |                      | 0.055  |
| No                                            | 32 | 4.0 (2.8–5.2)         |        | 12.0 (7.9–16.1)      |        |
| Current or former smoker                      | 30 | 2.5 (1.4–3.6)         |        | 7.0 (4.8–9.2)        |        |
| EGFR-TKI treatment                            |    |                       | 0.985  |                      | 0.593  |
| Yes                                           | 56 | 3.7 (2.4–5.0)         |        | 9.8 (6.4–13.2)       |        |
| No                                            | 6  | 2.1 (0–4.5)           |        | 4.9 (0–11.6)         |        |
| Previous treatment by paclitaxel or docetaxel |    |                       | 0.557  |                      | 0.873  |
| Yes                                           | 50 | 3.3 (2.2–4.4)         |        | 8.8 (5.5–12.1)       |        |
| No                                            | 12 | 3.9 (1.4–6.4)         |        | 10.7 (3.9–17.5)      |        |
| EGFR mutation                                 |    |                       | 0.291  |                      | 0.750  |
| Positive                                      | 21 | 4.4 (3.2–5.6)         |        | 8.8 (5.1–12.5)       |        |
| Negative                                      | 39 | 2.9 (1.6–4.2)         |        | 11.0 (6.4–15.6)      |        |

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; NSCLC, non-small cell lung cancer; OS, overall survival; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable disease.
Secreted protein acidic and rich in cysteine expression and its correlation to nanoparticle albumin-bound paclitaxel response

Only 28 of the patients included in the study were able to provide enough tumor tissue to test SPARC expression. We investigated SPARC expression in cancer and tumor stroma cells. In tumor stroma cells, SPARC expression was most clearly observed in the cytoplasm of peritumoral fibroblasts. The extracellular matrix and other local inflammatory cells (macrophages and lymphocytes) did not show SPARC expression. Nine patients (32.1%) were classified as cancer cell negative/tumor stroma cell negative, three (10.7%) as cancer cell positive/tumor stroma cell negative, three (10.7%) as cancer cell negative/tumor stroma cell positive, and 13 patients (46.5%) were classified as cancer cell positive/tumor stroma cell positive (Fig 3).

Because of the limited number of patients, we analyzed the associations of SPARC expression in cancer and tumor stroma cells with response to NAB-paclitaxel (Table 4). SPARC expression in tumor stroma cells was correlated with response to NAB-paclitaxel, with 5.0 and 3.3 months for SPARC negative and SPARC positive, respectively (Fig 4); \( P \) was statistically significant (\( P = 0.036 \)). However, there was no correlation between SPARC expression in cancer cells and response to NAB-paclitaxel.

Safety

Treatment was well tolerated in most patients receiving NAB-paclitaxel at the full dose (with the exception of two patients). All patients received 0.5–10 cycles (median four cycles) of NAB-paclitaxel monotherapy, while 10 received only 0.5–1 cycle of NAB-paclitaxel because of worsening symptoms. The most frequent treatment related AEs are presented in Table 5. The major grade 3–4 toxicities were leukopenia (6/64, 9.4%), neutropenia (5/64, 7.8%), and peripheral neuropathy (2/64, 3.1%). Other NAB-paclitaxel associated toxicities, including gastrointestinal AEs, rash, and anemia were mild to moderate and easily managed. Two patients had to discontinue chemotherapy because of drug induced serious fatigue and serious anorexia, respectively.

Discussion

Along with the development of targeted agents based on driver genes related to lung cancer and low toxicity chemotherapy, NSCLC patient survival, particularly in regard to lung adenocarcinoma, has been greatly improved. Prolongation of survival duration increases the opportunity for patients to receive multi-line treatment. Chemotherapy remains an important strategy, not only for EGFR wild-type patients, but also for patients with EGFR mutations.
However, to date, a therapeutic regimen after second or third-line treatment failure is still required. In our study, weekly administration of NAB-paclitaxel displayed convincing therapeutic efficacy in patients who had previously undergone multi-lines of therapy for advanced NSCLC and was well tolerated. More than 80% of the patients in this study received NAB-paclitaxel as fourth-line therapy or beyond, and the ORR and DCR were 16.1% and 64.5%, respectively, with a median PFS of 3.7 months (95% CI 2.6–4.8) and median OS of 9.8 months (95% CI 6.9–12.8). In particular, in the 10 patients who reached PR, eight had received 4–6 previous lines of therapy, including solvent-based paclitaxel or docetaxel, and all were categorized as clinical stage IV at the beginning of NAB-paclitaxel treatment. Similar circumstances occurred in patients who achieved SD. Previous phase III trials for second or third-line therapy of NSCLC patients have reported ORRs of 7.6–9.1%, median PFS of 2.0–2.9 months, and median OS of 6.7–8.3 months. In this study, more than 50% of patients received at least four cycles of NAB-paclitaxel. More than half of the patients had multiple comorbidities, such as hypertension, diabetes, hepatitis B, and heart disease, which inevitably affected functional status, general health, and chemotherapy tolerance. Overall, a weekly dose of 130 mg/m² NAB-paclitaxel was well tolerated and no treatment-related death occurred. Patients who were not treated with corticosteroids before NAB-paclitaxel experienced no hypersensitivity. In a randomized phase III trial, compared directly

### Table 4 SPARC expression status in cancer or tumor stroma cells with response to NAB-paclitaxel

| SPARC expression status                  | No. of patients | PFS (m) 95% CI  | P     | OS (m) 95% CI  | P     |
|-----------------------------------------|-----------------|----------------|-------|----------------|-------|
| Positive in cancer cell                 | 16              | 3.7 (2.9–4.5)  | 0.342 | 11.5 (3.0–24.0) | 0.627 |
| Negative in cancer cell                 | 12              | 4.3 (0.7–7.9)  |       | 12.0 (3.0–21.0) |       |
| Positive in tumor stroma cell           | 16              | 3.3 (0.6–6.0)  | 0.036 | 11.5 (1.1–21.9) | 0.718 |
| Negative in tumor stroma cell           | 12              | 5.0 (2.4–7.6)  |       | 12.2 (3.0–21.0) |       |

CI, confidence interval; m, months; NAB, nanoparticle albumin-bound; OS, overall survival; PFS, progression-free survival; SPARC, secreted protein acidic and rich in cysteine.
with solvent-based paclitaxel plus carboplatin, a weekly dose of 100 mg/m² NAB-paclitaxel (on days 1 and 8) plus carboplatin administered every three weeks showed significantly higher response rates and time to progression, with a decreased incidence of grade 4 neutropenia in 1038 untreated patients with stage IIIb–IV NSCLC. However, as anticipated with a higher paclitaxel dose, dose-limiting toxicities included 0.5% grade 3 and 4 peripheral neuropathy in the NAB-paclitaxel group compared with 2.3% in the solvent-based paclitaxel group (P < 0.001). In our study, the major grade 3–4 toxicities were leukopenia (6/64, 9.4%), neutropenia (5/64, 7.8%), and peripheral neuropathy (2/64, 3.1%), which were resolved with appropriate support treatment. Peripheral neuropathy was mild to moderate and was alleviated when NAB-paclitaxel treatment was discontinued. Weekly administration of NAB-paclitaxel seems to be an ideal regimen for NSCLC patients, especially when the use of steroids is contraindicated or after multiple lines of treatment.

Because solvent-based paclitaxel or docetaxel is the standard first or second-line therapy regimen, it is necessary to determine whether traditional taxane may influence subsequent NAB-paclitaxel therapy. Our data showed that previous treatment with solvent-based paclitaxel or doce-taxel did not affect the response to NAB-paclitaxel. Similar results were observed in several prospective clinical trials, for example, in breast cancer patients who had failed previous taxane treatment received NAB-paclitaxel. As such, we conclude that previous taxane therapy does not affect the response to NAB-paclitaxel, which might be attributed to the different action mechanisms of the two kinds of agents. However, we found that the patients who achieved disease control after solvent-based paclitaxel or docetaxel administration benefitted more from NAB-paclitaxel than patients who did not, although the result did not reach statistical significance. This may be a result of NAB technology, which, when albumin with paclitaxel particles are combined, enables a greater amount of NAB-paclitaxel to enter the tumor tissue, with high intra-tumor drug concentration.

Whether SPARC expression is a predictor for NAB-paclitaxel therapy remains controversial. A study by Desal et al. showed that SPARC might be a predictive biomarker of response to NAB-paclitaxel. An opposing result was

Table 5 Most frequent treatment-related adverse events (n = 64)

| Toxicity                     | All     | Maximum grade, no. of patients (%) |
|------------------------------|---------|-----------------------------------|
|                              | 1       | 2       | 3       | 4       |
| Leukopenia                   | 23 (35.9%) | 8 (12.5%) | 9 (14.1%) | 2 (3.1%) | 4 (6.3%) |
| Neutropenia                  | 19 (29.7%) | 6 (9.4%) | 8 (12.5%) | 2 (3.1%) | 3 (4.7%) |
| Peripheral neuropathy        | 16 (25.0%) | 12 (18.8%) | 2 (3.1%) | 2 (3.1%) | 0 |
| Nausea/Vomiting              | 7 (10.9%) | 6 (9.4%) | 1 (1.5%) | 0 | 0 |
| Elevated ALT/AST             | 4 (6.3%) | 2 (3.1%) | 2 (3.1%) | 0 | 0 |
| Fatigue                      | 5 (7.8%) | 2 (3.1%) | 1 (1.5%) | 1 (1.5%) | 1 (1.5%) |
| Rash                         | 2 (3.1%) | 0 | 2 (3.1%) | 0 | 0 |
| Anemia                       | 3 (4.7%) | 0 | 2 (3.1%) | 1 (1.5%) | 0 |

ALT, alanine transaminase; AST, aspartate transaminase.
reported by Schneeweiss et al. in that the efficacy of NAB-paclitaxel did not seem to be associated with SPARC expression in metastatic breast cancer, in either tumor tissues or plasma samples. Koukourakis et al. analyzed SPRAC expression in 113 tumor samples from patients with early operable NSCLC. The results showed that stroma SPARC expression was linked with tumor necrosis and SPARC production by stroma cells supported a high degree of vascular maturation. Survival analysis demonstrated a significant association between stroma SPARC and poor prognosis ($P = 0.006$). However, the authors did not collect treatment data for these patients after disease relapse or progression and, thus, could not evaluate the relationship between stroma SPARC expression and response to NAB-paclitaxel. Our study showed that SPARC expression in tumor stroma cells, but not in cancer cells, was correlated with response to NAB-paclitaxel. To the best of our knowledge, this is the first time the relationship between SPARC expression in tumor stroma or cancer cells and response to NAB-paclitaxel has been investigated. However, because of the limited number of patients and the retrospective feature of this study, the predictive role of SPARC expression in tumor stroma cells to NAB-paclitaxel needs to be verified by a large sample study.

There were some limitations to our study. First, this is a retrospective study and all of the patients received NAB-paclitaxel as third-line or further treatment. In the real world, few patients accept subsequent biopsies during their disease course because of multiple reasons, including personal wishes or the difficult location of a nodule for needle biopsy. Therefore, we could only evaluate SPARC expression in the tumor samples available, and these were not real time subsequent biopsies performed before NAB-paclitaxel administration. Second, the number of enrolled patients was limited, which may lead to selection bias. Because of the expense of NAB-paclitaxel and the fact that it is not covered by medical insurance, this treatment is limited to those that can afford it. These factors indicate that we must evaluate the results of our study with caution.

In conclusion, NAB-paclitaxel displays convincing antitumor activity for the management of advanced NSCLC, even in patients who have received multiple lines of treatment. With a high therapeutic index and low side effects, weekly NAB-paclitaxel administration seems to have the ideal clinical benefit-risk ratio. A large-scale, prospective, randomized clinical study is required to provide supportive data for this regimen.

Acknowledgment

We wish to thank the patients and family members who participated in this study. We are grateful to Dr. Zhonghu He for statistics and Dr. Liping Qi for response assessment contributions. Pathologists Dr. Yu Sun and Dr. Yiqiang Liu evaluated the SPARC expression in cancer and tumor stroma cells in this study and we are very appreciative of their support.

Disclosure

No authors report any conflict of interest.

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5–29.
2. Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol 2012; 7: 1361–8.
3. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8.
4. Socinski MA. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. Oncologist 1999; 4: 408–16.
5. Green MR, Manikhas GM, Orlov S et al. Abraxane, a novel Cremophor-free, albumin- bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17: 1263–8.
6. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8: 1038–44.
7. Schiennmann BJ, Neil JR, Schiennmann WP. SPRAC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol Biol Cell 2003; 14: 3977–88.
8. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. (Published erratum appears in Clin Cancer Res 2006; 12: 3869) Clin Cancer Res 2006; 12: 1317–24.
9. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003; 284: L187–96.
10. Ibrahim NK, Samuels B, Page R et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23: 6019–26.
11. Socinski MA, Manikhas GM, Stroyakovskiy DL et al. A dose finding study of weekly and every-3-week nab-paclitaxel followed by carboplatin as first-line therapy in patients with...
advanced non-small cell lung cancer. J Thorac Oncol 2010; 5: 852–61.

12 Rizvi NA, Riely GJ, Azzoli CG et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26: 639–43.

13 Socinski MA, Bondarenko I, Karaseva NA et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012; 30: 2055–62.

14 Xing PY, Li JL, Wang Y et al. Efficacy and safety of albumin-bound paclitaxel in treating recurrent advanced non-small-cell lung cancer. Chin J Cancer Res 2013; 25: 200–5.

15 Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonecrosis promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 1999; 59: 4453–7.

16 Briggs J, Chamboredon S, Castellazzi M, Kerry JA, Bos Tj. Transcription upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene 2002; 21: 7077–91.

17 Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical significance of secreted protein acidic and rich in cysteine in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003; 97: 2412–9.

18 Watkins G, Douglas-Jones A, Bryce R, Mansel RE, Jiang WG. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 267–72.

19 Handrich SJ, Hough DM, Fletcher JG, Sarr MG. The natural history of the incidentally discovered small simple pancreatic cyst: Long-term follow-up and clinical implications. AJR Am J Roentgenol 2005; 184: 20–3.

20 Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004; 91: 1924–30.

21 Infante JR, Matsubayashi H, Sato N et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007; 25: 319–25.

22 Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103.

23 Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.

24 Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.

25 Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomized phase III trial. Lancet 2008; 372: 1809–18.

26 Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX320 Non-Small Cell Lung Cancer Study Group. (Published erratum appears in J Clin Oncol 2004; 22: 209.) J Clin Oncol 2000; 18: 2354–62.

27 Blum JL, Savin MA, Edehnan G et al. Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 2007; 7: 850–6.

28 Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced non-hematologic malignancies. J Clin Oncol 2005; 23: 7785–93.

29 Desai N, Trieu V, Knauer D et al. SPARC may be a predictive biomarker of response to nab-paclitaxel. Eur J Cancer 2009; 7 (2): 88.

30 Schneeweiss A, Seitz J, Smetanay K et al. Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Res 2014; 34: 6609–15.

31 Koukourakis MI, Giatromanolaki A, Brekken RA et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003; 63: 5376–80.